Cefditoren: Comparative efficacy with other antimicrobials and risk factors for resistance in clinical isolates causing UTIs in outpatients

BMC Infectious Diseases

Volumn 12, Issue , 2012, Pages

  Hatzaki, Despina ^a   Poulakou, Garyphallia ^b   Katsarolis, Ioannis ^b   Lambri, Niki ^b   Souli, Maria ^b   Deliolanis, Ioannis ^c   Nikolopoulos, Georgios K ^d   Lebessi, Evangelia ^a   Giamarellou, Helen ^b,e  

^a P AND A KYRIAKOU CHILDREN S HOSPITAL   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c KAT HOSPITAL   (Greece)

^d Hellenic Centre for Disease Control and Prevention   (Greece)

^e HYGEIA HOSPITAL   (Greece)

Author keywords

Acute uncomplicated cystitis; Antimicrobial resistance; Cephalosporins; Empirical treatment; Urinary tract infections

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; BETA LACTAMASE AMPC; CEFALOTIN; CEFDITOREN; CEFOTAXIME; CEFTAZIDIME; CEFUROXIME; CEFUROXIME AXETIL; CIPROFLOXACIN; COTRIMOXAZOLE; EXTENDED SPECTRUM BETA LACTAMASE; FOSFOMYCIN; GENTAMICIN; IMIPENEM; MECILLINAM; NALIDIXIC ACID; NETILMICIN; NITROFURANTOIN; PIPERACILLIN PLUS TAZOBACTAM; TIMENTIN;

ADOLESCENT; AGAR DILUTION; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; ESCHERICHIA COLI; FEMALE; GROWTH INHIBITION; HUMAN; IN VITRO STUDY; KLEBSIELLA; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; OUTPATIENT; PROTEUS MIRABILIS; RISK FACTOR; URINARY TRACT INFECTION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; DRUG RESISTANCE, BACTERIAL; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; FEMALE; GREECE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; OUTPATIENTS; PREGNANCY; RISK FACTORS; TREATMENT OUTCOME; URINARY TRACT INFECTIONS; YOUNG ADULT;

EID: 84866560987     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-12-228     Document Type: Article

References (23)

1. Ronald A. The etiology of urinary tract infection: traditional and emerging pathogens. Am J Med 2002, 113(Suppl 1A):14S-19S.
2. Naber KG, Schito G, Botto H, Palou J, Mazzei T. Surveillance study in Europe and Brazil on clinical aspects and Antimicrobial Resistance Epidemiology in Females with Cystitis (ARESC): implications for empiric therapy. Eur Urol 2008, 54:1164-1175. 10.1016/j.eururo.2008.05.010, 18511178.
3. Gupta K, Hooton TM, Naber KG, Wullt B, Colgan R, Miller RG, Moran GJ, Nicolle LE, Raz R, Schaeffer AJ, Soper DE. International Clinical Practice Guidelines for the Treatment of Acute Uncomplicated Cystitis and Pyelonephritis in Women: A 2010 Update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis 2011, 52:e103-e120. 10.1093/cid/ciq257, 21292654.
4. Paterson DL. "Collateral damage" from cephalosporin or quinolone antibiotic therapy. Clin Infect Dis 2004, 38(Suppl. 4):S341-S345.
5. Hillier S, Bell J, Heginbothom M, Roberts Z, Dunstan F, Howard A, Mason B, Butler CC. When do general practitioners request urine specimens for microbiology analysis? The applicability of antibiotic resistance surveillance based on routinely collected data. J Antimicrob Chemother 2006, 58:1303-1306. 10.1093/jac/dkl432, 17062608.
6. Talan DA, Krishnadasan A, Abrahamian FM, Stamm WE, Moran GJ. Prevalence and risk factor analysis of trimethoprim-sulfamethoxazole- and fluoroquinolone-resistant Escherichia coli infection among emergency department patients with pyelonephritis. Clin Infect Dis 2008, 47:1150-1158. 10.1086/592250, 18808361.
7. Jones RN, Biedenbach DJ, Johnson DM. Cefditoren activity against nearly 1000 non-fastidious bacterial isolates and the development of in vitro susceptibility test methods. Diagn Microbiol Infect Dis 2000, 37:143-146. 10.1016/S0732-8893(00)00135-8, 10863109.
8. Biedenbach DJ, Jones RN. Update of cefditoren activity tested against community-acquired pathogens associated with infections of the respiratory tract and skin and skin structures, including recent pharmacodynamic considerations. Diagn Microbiol Infect Dis 2009, 64:202-212. 10.1016/j.diagmicrobio.2009.01.017, 19321284.
9. Sevillano D, Aguilar L, Alou L, Giménez MJ, Torrico M, González N, Cafini F, Relaño MT, Coronel P, Prieto J. Urine bactericidal activity against Escherichia coli isolates exhibiting different resistance phenotypes/genotypes in an in vitro pharmacodynamic model simulating urine concentrations obtained after oral administration of a 400-milligram single dose of cefditoren-pivoxil. Antimicrob Agents Chemother 2008, 52:1184-1186. 10.1128/AAC.01247-07, 2258530, 18160517.
10. Katsarolis I, Poulakou G, Athanasia S, Kourea-Kremastinou J, Lambri N, Karaiskos E, Panagopoulos P, Kontopidou FV, Voutsinas D, Koratzanis G, Kanellopoulou M, Adamis G, Vagiakou H, Perdikaki P, Giamarellou H, Kanellakopoulou K. Collaborative Study Group on Antibiotic Resistance in Community-acquired Urinary Tract Infections: Acute uncomplicated cystitis: from surveillance data to a rationale for empirical treatment. Int J Antimicrob Agents 2010, 35:62-67. 10.1016/j.ijantimicag.2009.08.018, 19906513.
11. Clinical and Laboratory Standards Institute Performance Standards for Antimicrobial Susceptibility Testing 2011, Wayne: CLSI, Twenty-First Informational Supplement, M100 - S21, Clinical and Laboratory Standards Institute.
12. Darkes MJ, Plosker GL. Cefditoren pivoxil. Drugs 2002, 62:319-336. 10.2165/00003495-200262020-00006, 11817976.
13. Ko KS, Suh JY, Lee MY, Lee NY, Peck KR, Kwon KT, Jung DS, Song JH. In vitro activity of cefditoren against clinical isolates of Escherichia coli from a Korean hospital. Int J Antimicrob Agents 2007, 30:283-285. 10.1016/j.ijantimicag.2007.05.011, 17651945.
14. Cuevas O, Cercenado E, Gimeno M, Marin M, Coronel P, Bouza E. Comparative in vitro activity of cefditoren and other antimicrobials against Enterobacteriaceae causing community-acquired uncomplicated urinary tract infections in women: a Spanish nationwide multicenter study. Diagn Microbiol Infect Dis 2010, 67:251-260. 10.1016/j.diagmicrobio.2010.02.013, 20542206.
15. European Committee on Antimicrobial Susceptibility Testing available at: http://www.eucast.org/eucast_disk_diffusion_test/breakpoints/.
16. Tenover FC, Emery SL, Spiegel CA, Bradford PA, Eells S, Bonomo RA EA, McGowan JE. Identification of plasmid-mediated AmpC beta-lactamases in Escherichia coli, Klebsiella spp. and Proteus species can potentially improve reporting of cephalosporin susceptibility testing results. J Clin Microbiol 2009, 47:294-299. 10.1128/JCM.01797-08, 2643671, 19036936.
17. Kahlmeter G, Poulsen HO. Antimicrobial susceptibility of Escherichia coli from community-acquired urinary tract infections in Europe: the ECO·SENS study revisited. Int J Antimicrob Agents 2012, 39:45-51. 10.1016/j.ijantimicag.2011.09.013, 22055529.
18. Kahlmeter G, ECO.SENS An international survey of the antimicrobial susceptibility of pathogens from uncomplicated urinary tract infections: the ECO.SENS Project. J Antimicrob Chemother 2003, 51:69-76. 10.1093/jac/dkg028, 12493789, ECO.SENS.
19. Hillier S, Roberts Z, Dunstan F, Butler C, Howard A, Palmer S. Prior antibiotics and risk of antibiotic-resistant community-acquired urinary tract infection: a case-control study. J Antimicrob Chemother 2007, 60:92-99. 10.1093/jac/dkm141, 17540675.
20. Hooton TM, Besser R, Foxman B, Fritsche TR, Nicolle LE. Acute uncomplicated cystitis in an era of increasing antibiotic resistance: a proposed approach to empirical therapy. Clin Infect Dis 2004, 39:75-80. 10.1086/422145, 15206056.
21. Guidelines for the Diagnosis and Empirical Treatment of Infections 2007, Athens: Hellenic Center for the Disease Control and Prevention, available at http://www.keelpno.gr/Portals/Infections_Book.pdf.
22. Johnson L, Sabel A, Burman WJ, Everhart RM, Rome M, MacKenzie TD, Rozwadowski J, Mehler PS, Price CS. Emergence of fluoroquinolone resistance in outpatient urinary Escherichia coli isolates. Am J Med 2008, 121:876-884. 10.1016/j.amjmed.2008.04.039, 18823859.
23. Quinolone Restriction Formulary implemented by the Hellenic Drug Administration (EOF) available at http://eof1.eof.gr/html/law.html.